Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

• Annovis Bio’s lead drug candidate buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients
• In a short-term Phase 2/3 study, buntanetap has been shown to work three times better than the standard of care in the market
• The company plans further clinical trials to validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association International Conference(R) 2024 (AAIC(R)) in Philadelphia. Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of the company detailed these findings, as well as the scientific community’s response and the company’s future plans, during a recent episode of IBN’s Bell2Bell Podcast with Stuart Smith, recorded live at the AAIC.

Dr. Maccecchini explained that this was a short-term study with 360 participants, all in the early stages of Alzheimer’s disease. The response to buntanetap was excellent, as the drug candidate was shown to be at least three times better than the standard of care available in the market. The results were welcomed by the scientific community, (https://ibn.fm/oiZAi).

“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve learning, memory and quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”

Annovis now plans to repeat the short-term study with a higher number of participants (600 patients), and to also ask the Food and Drug Administration to approve the extension of the short-term study to 18 months in order to show that buntanetap works both in the short- and long-term. The company is looking to complete the short study and submit a request for approval before the end of next year.

The neurodegenerative disease treatment market is substantial and growing, driven by an aging population and increasing incidence of conditions like Alzheimer’s disease. Nearly 7 million Americans are currently suffering from Alzheimer’s, a figure projected to rise to almost 13 million by 2050. Alzheimer’s care costs are expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050 (https://ibn.fm/AsPB8).

Buntanetap, formerly known as Posiphen, is designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases. This multi-targeted approach positions buntanetap as a potential breakthrough in treating these debilitating conditions.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN